Skip to main content

Pollen Allergy

1
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Allergopharma
AllergopharmaGermany - Reinbek
1 program
1
birch pollen allergoidPhase 3
Mabylon
MabylonSwitzerland - Schlieren
1 program
blood withdrawalN/A1 trial
Active Trials
NCT03727399Enrolling By Invitation300Est. Dec 2030

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Mabylonblood withdrawal

Clinical Trials (1)

Total enrollment: 300 patients across 1 trials

NCT03727399Mabylonblood withdrawal

Identification of Allergen-reactive Antibodies in the Blood of Pollen Allergic Patients

Start: Oct 2018Est. completion: Dec 2030300 patients
N/AEnrolling By Invitation

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.